Seaport Therapeutics began trading on the Nasdaq after executives rang the opening bell, following its initial public listing. The company is associated with a leadership bench largely drawn from Karuna Therapeutics veterans, positioning Seaport as a neuropsychiatric-drugs specialist. In parallel, the reporting notes that the parent entity Puretech Health planned changes to its listing strategy, opting for a sole listing on the London Stock Exchange to reduce cost base and bureaucracy. Seaport raised gross proceeds of $254.9 million at the time of the Nasdaq debut. For investors, the listing is an early signal of how carve-out and parent reorganization strategies are being used to fund CNS pipeline execution on public markets.